Gongwin Biopharm Holdings Co., Ltd. (6617.TWO)
TWD 111.5
(1.36%)
TWD 111.5
(1.36%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -110.79 Million | -232.19 Million | -95.5 Million | -87.26 Million | - |
| Net Income | -101.17 Million | -292.13 Million | -114.72 Million | -99.31 Million | - |
| Depreciation & Amortization | 13.32 Million | 13.38 Million | 12.95 Million | 12.53 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | 29.28 Million | 568 Thousand | 11.02 Million | - |
| Change in working capital | -21.92 Million | 22.09 Million | 8.91 Million | -4.89 Million | - |
| Other non-cash items | -34.99 Million | -5.22 Million | -3.67 Million | -7.37 Million | - |
| Investing Cash Flow | -280.96 Million | -202 Million | -246.41 Million | 77.04 Million | - |
| Investments in PPE | -224 Thousand | -6.17 Million | -54 Thousand | -30.13 Million | - |
| Acquisitions | 23.82 Million | - | - | - | - |
| Investment purchases | -791.08 Million | -449.59 Million | -562.47 Million | -502.71 Million | - |
| Sales/Maturities of investments | 511.24 Million | 255.09 Million | 438.71 Million | 609.89 Million | - |
| Other Investing Activities | -1.13 Million | -170 Thousand | 355 Thousand | - | -16 Thousand |
| Financing Cash Flow | -12.1 Million | 604.04 Million | 101.77 Million | 541.42 Million | - |
| Debt repayment | -62.34 Million | -20.29 Million | -83.83 Million | -8.37 Million | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 11.95 Million | 575.41 Million | 22.65 Million | 538.83 Million | - |
| Other Financing Activities | 43.33 Million | 13.23 Million | 4000.00 | - | 24.12 Million |
| Accounts receivables | -10.58 Million | - | - | - | - |
| Accounts payables | 287 Thousand | - | - | - | - |
| Inventory | -11.71 Million | -211 Thousand | - | - | - |
| Other working capital | 372 Thousand | - | - | - | - |
| Cash at beginning of period | 671.51 Million | 454.12 Million | 707.23 Million | 189.69 Million | - |
| Cash at end of period | 273.58 Million | 671.51 Million | 454.12 Million | 707.23 Million | - |
| Capital Expenditure | -224 Thousand | -6.17 Million | -54 Thousand | -30.13 Million | - |
| Effect of forex changes on cash | 5.94 Million | 47.54 Million | -12.95 Million | -13.67 Million | - |
| Net cash flow / Change in cash | -397.92 Million | 217.38 Million | -253.11 Million | 517.53 Million | - |
| Free Cash Flow | -111.02 Million | -238.37 Million | -95.56 Million | -117.39 Million | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -26.48 Million | -26.91 Million | -101.17 Million | -35.62 Million | -17.17 Million | -24.31 Million |
| Depreciation & Amortization | 2.76 Million | 3.11 Million | 13.32 Million | 3.23 Million | 3.33 Million | 3.37 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -4.15 Million | 3.91 Million | -21.92 Million | 4.45 Million | -14.72 Million | 4.16 Million |
| Other non-cash items | -9.11 Million | -10.87 Million | -34.99 Million | -12.39 Million | -4.1 Million | -13.25 Million |
| Investing Cash Flow | 236.92 Million | -64.02 Million | -280.96 Million | 22.8 Million | -112.71 Million | -44.73 Million |
| Investments in PPE | -178.27 Million | -21.18 Million | -224 Thousand | 855 Thousand | -411 Thousand | -485 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -34.48 Million | -198.45 Million | -791.08 Million | -275.07 Million | -299.92 Million | -44.94 Million |
| Sales/Maturities of investments | 448.8 Million | 155.62 Million | 511.24 Million | 297.93 Million | 187.63 Million | 691 Thousand |
| Other Investing Activities | 415.19 Million | - | - | - | - | - |
| Financing Cash Flow | 2.14 Billion | 14.21 Million | -12.1 Million | -1.56 Million | -49.35 Million | 18.69 Million |
| Debt repayment | -157.51 Million | -6.5 Million | -62.34 Million | -7.56 Million | -82.31 Million | -7.7 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 1.98 Billion | - | 11.95 Million | - | - | 8.77 Million |
| Other Financing Activities | 133 Thousand | 8.96 Million | 43.33 Million | -7.87 Million | 34.2 Million | 3.45 Million |
| Accounts receivables | -3.79 Million | - | - | - | - | - |
| Accounts payables | 1000.00 | - | - | - | - | - |
| Inventory | -92 Thousand | -257 Thousand | -11.71 Million | 698 Thousand | -391 Thousand | -12.02 Million |
| Other working capital | 3.17 Million | - | - | - | - | - |
| Cash at beginning of period | 204.12 Million | 273.58 Million | 671.51 Million | 275.6 Million | 458.13 Million | 501.21 Million |
| Cash at end of period | 2.58 Billion | 204.12 Million | 273.58 Million | 273.58 Million | 275.6 Million | 458.13 Million |
| Capital Expenditure | -178.27 Million | -21.18 Million | -224 Thousand | 855 Thousand | -411 Thousand | -485 Thousand |
| Effect of forex changes on cash | 12.03 Million | 7.68 Million | 5.94 Million | -4.59 Million | 6.04 Million | 9.28 Million |
| Net cash flow / Change in cash | 2.38 Billion | -69.46 Million | -397.92 Million | -2.01 Million | -182.52 Million | -43.07 Million |
| Free Cash Flow | -188.13 Million | -48.51 Million | -111.02 Million | -17.8 Million | -26.91 Million | -26.81 Million |
9685
YGFGF
SQFTP
MLGCF
0118
002408